PMID- 18370778
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20220409
IS  - 1557-8518 (Electronic)
IS  - 1540-4196 (Linking)
VI  - 5
IP  - 3
DP  - 2007 Sep
TI  - Metabolic syndrome in type 2 diabetes mellitus in isfahan, iran: prevalence and 
      risk factors.
PG  - 243-54
LID - 10.1089/met.2005.0010 [doi]
AB  - BACKGROUND: Our goal was to estimate the prevalence and risk factors of metabolic 
      syndrome (MetSyn) in people with type 2 diabetes mellitus (T2DM) using routinely 
      collected data from a clinical information system at Isfahan Endocrinology and 
      Metabolism Research Centre, Iran. METHODS: Consecutive diabetic patients (9889 
      total, 4164 male and 5725 female) from Isfahan Endocrinology and Metabolism 
      Research Centre outpatient clinics, Iran, have been examined. The mean (SD) age 
      of participants was 52.0 (10.9) years with a mean (standard deviation) duration 
      of diabetes of 6.4 (6.4) years at initial registration. A modified National 
      Cholesterol Education Program-Adult Treatment Panel III definition with body mass 
      index instead of waist circumference was used for the MetSyn. RESULTS: The 
      prevalence of MetSyn was 65.0% [95% confidence interval (CI) 64.0, 65.9], with 
      higher rate in females than males (71.7 [95% CI: 70.5, 72.8] female and 55.8 [95% 
      CI: 54.3, 57.3] male) and it was greater with older age. The age-adjusted 
      prevalence rate of MetSyn was associated with female gender, duration of 
      diabetes, fasting blood glucose, systolic and diastolic blood pressure, body mass 
      index (BMI), smoking, proteinuria, insulin-treatment, triglyceride, cholesterol, 
      HDL cholesterol, hypertension, and dyslipidemia. Using a stepwise binary logistic 
      regression model, age, gender, fasting blood glucose, systolic and diastolic 
      blood pressure, BMI, triglyceride, and cholesterol were significant predictors of 
      MetSyn for T2DM patients. CONCLUSIONS: These data suggest MetSyn in this 
      population of Iranian type 2 diabetic patients is common, and with an estimated 
      prevalence of 65%, MetSyn clearly poses a formidable health threat to Iranian 
      diabetic patients. Lifestyle interventions in T2DM subjects are needed in Iran to 
      halt the burden of macro- and micro-vascular complications in T2DM.
FAU - Janghorbani, Mohsen
AU  - Janghorbani M
AD  - Department Of Epidemiology and Isfahan Endocrinology and Metabolism Research 
      Centre, Isfahan University of Medical Sciences and Health Services, Iran.
FAU - Amini, Masoud
AU  - Amini M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Metab Syndr Relat Disord
JT  - Metabolic syndrome and related disorders
JID - 101150318
EDAT- 2008/03/29 09:00
MHDA- 2008/03/29 09:01
CRDT- 2008/03/29 09:00
PHST- 2008/03/29 09:00 [pubmed]
PHST- 2008/03/29 09:01 [medline]
PHST- 2008/03/29 09:00 [entrez]
AID - 10.1089/met.2005.0010 [doi]
PST - ppublish
SO  - Metab Syndr Relat Disord. 2007 Sep;5(3):243-54. doi: 10.1089/met.2005.0010.